Becaplermin

Phase 3Protein / enzyme

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Becaplermin is one of 29 small molecule programs targeting Wound Healing. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wound HealingActive, not recruiting

Wound HealingPhase 3

Active, not recruiting

Competition

Competitive Landscape

133 competitors in Wound Healing

#DrugCompanyPhaseTrials

Januvia

ZZydus Therapeutics Inc.

Phase 3

1 2

Avastin

BBio-Thera Solutions

Phase 3

1 3

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 4

Glucophage

EMD Serono

Phase 3

1 5

Growth Hormone

Pfizer

Phase 3

1 6

Vaseline

MMassachusetts General Hospital

Phase 3

1 7

Oxandrolone

PPar Pharmaceutical, Inc.

Phase 3

1 8

Becaplermin

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 9

Oxandrolone and Propranolol

TThe University of Texas Medical Branch, Galveston

Phase 3

1 10

Nicorette

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetes1 trial

Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.··NCT01235260

Hypertensive1 trial

Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00970697·64 enrolled

Wound Healing1 trial

Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing

Unknown status·MMcMaster University·Phase 3·NCT02845466·80 enrolled

Efficacy and Safety1 trial

A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00034788·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Becaplermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Becaplermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Becaplermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Becaplermin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetes1 trial

Hypertensive1 trial

Wound Healing1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News